Ceftazidime-Avibactam Treatment for Carbapenemase-Producing Enterobacterales in a South African Children's Hospital

This study describes ceftazidime-avibactam use in 17 young children from a resource-constrained country, where intra-abdominal infection was common. All-cause mortality was 53%. Earlier initiation, dose optimization, recording infusion times, and reviewing the need for additional antibiotics were identified as easy-to-implement-antimicrobial-stewardship interventions. Limited safety and efficacy data, consisting mostly of observational data from well-resourced countries, for the treatment of carbapenem-resistant Enterobacterales (CRE)-infection in children exist. This study generated insights into ceftazidime-avibactam for the treatment of CRE infection particularly in young children from a resource-constrained country.